Hidden Genetic Triggers of Heart Disease Risk Unveiled

Heart Disease Genetics Concept

Researchers have created a new method to link genetic variants to coronary artery disease, discovering a connection to a rare vascular disease, which may lead to new treatments. Credit: SciTechDaily.com

New gene mapping technique reveals how genetic alterations in cells lining blood vessels contribute to coronary artery disease, with implications for diagnostic and treatment strategies.

  • Researchers from the Brigham, the Broad Institute, and Stanford Medicine studied how “deleting” individual genes associated with coronary artery disease (CAD) impacted the expression of all the other genes in a cell to better understand underlying biology of CAD.
  • The study focused on endothelial cells, which line blood vessels and are increasingly understood to influence CAD risk.
  • The researchers highlighted a previously unrecognized role for the TLNRD1 gene and hypothesized that this gene may be involved in both CAD, a common disease, and cerebral cavernous malformations, a rare one.
  • The shared genetic risk for common and rare vascular diseases is an opportunity for future diagnosis and therapy.

New Mapping Technique Advances Heart Disease Research

Over the past 15 years, researchers have identified hundreds of regions in the human genome associated with heart attack risk. However, researchers lack efficient ways to explore how these genetic variants are molecularly connected to cardiovascular disease, limiting efforts to develop therapeutics.

To streamline the analysis of hundreds of genetic variants associated with coronary artery disease (CAD), a team of researchers led by investigators from Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, in collaboration with the Broad Institute of MIT and Harvard and Stanford Medicine, combined multiple sequencing and experimental techniques to map the relationship between known CAD variants and the biological pathways they impact.

In a study published in Nature, the researchers applied this technique to endothelial cells, which line blood vessels. The team found that a key biological mechanism involved in a rare vascular disease may influence CAD risk.

“Studying how hundreds of regions of the genome, individually or in groups, influence risk of heart attack can be a painstaking process,” said corresponding author Rajat Gupta, MD, of the Divisions of Genetics and Cardiovascular Medicine at Brigham and Women’s Hospital.

“We decided we needed to have better maps showing how genetic variants affect gene expression and how genes affect biological function. If we could combine those two kinds of maps, we could make the bigger connection from variant to biological function.”

Groundbreaking V2G2P Approach in Genomic Research

The mapping technique developed by the researchers is called the Variant-to-Gene-to-Program (V2G2P) approach. First, in collaboration with researchers at Stanford Medicine, the researchers matched CAD loci previously identified through genome-wide association studies to genes impacted by these genetic variants. Then, they used CRISPRi-Perturb-seq, a technology developed at the Broad Institute of MIT and Harvard, to “delete” thousands of CAD-associated genes, one at a time, and to examine how each deletion impacted the expression of all the other genes in that cell.

In total, the researchers sequenced 215,000 endothelial cells to determine how 2,300 “deletions” influenced expression of 20,000 other genes in each cell. With applied machine learning algorithms, they were able to identify the biological mechanisms that consistently appeared to be related to CAD-associated variants.

In particular, the researchers found that 43 of 306 of the CAD-associated variants in endothelial cells were linked to genes in the cerebral cavernous malformations (CCM) signaling pathway. CCM is a rare, devasting vascular disease that impacts the brain, but the researchers hypothesized that smaller, subtler mutations in the genes involved in CCM may contribute to CAD risk by affecting vascular inflammation, thrombosis, and the structural integrity of the endothelium. Moreover, the researchers highlighted a previously unrecognized role for the TLNRD1 gene in regulating the CCM pathway alongside other known CCM regulators and hypothesized that TLNRD1 may be involved in both CAD, a common disease, and CCM, a rare one.

Implications for CAD and CCM Treatment

Going forward, the researchers hope to study patients with endothelial CAD-associated variants as well as CCM patients to determine whether there are distinct opportunities for treating these populations. For the latter, the researchers are interested in determining whether further investigation into TLNRD1 can lead to better forms of genetic testing and risk stratification.

This study focused on endothelial cells, which line blood vessels and are increasingly understood to influence CAD risk. It examined endothelial mechanisms unrelated to lipid metabolism (a known driver of CAD risk with effective therapies, like statins) in hopes of uncovering other mechanisms driving CAD risk for which therapies may yet be developed.

“Now that we know more about this collection of endothelial cell variants, we can return to patients who have them to see if they have different clinical features or respond differently to the therapies we are already using,” Gupta said. “We are also focused on this study’s implications for CCM patients. It was a coincidence that from this genetic screen designed to look at coronary disease, we implicated new genes for a rare vascular disease, CCM. Perhaps now we can better describe the risk factors and pathways that drive it.”

Expanding Research Horizons Beyond CAD

Beyond CAD and CCM, the researchers emphasize that the V2G2P approach can be used to explore the biological mechanisms driving any disease for which a cell type relevant to that disease can be genetically modified in the lab.

“It was remarkable that this unbiased, systematic approach — in which we deleted all candidate CAD genes in a single experiment — pointed us straight to new genes and pathways that had escaped notice. This approach will be a powerful strategy for studying many other diseases where genetic risk factors remain to be discovered,” said co-corresponding author Jesse Engreitz, PhD, assistant professor of genetics at Stanford Medicine.

Reference: “Convergence of coronary artery disease genes onto endothelial cell programs” by Gavin R. Schnitzler, Helen Kang, Shi Fang, Ramcharan S. Angom, Vivian S. Lee-Kim, X. Rosa Ma, Ronghao Zhou, Tony Zeng, Katherine Guo, Martin S. Taylor, Shamsudheen K. Vellarikkal, Aurelie E. Barry, Oscar Sias-Garcia, Alex Bloemendal, Glen Munson, Philine Guckelberger, Tung H. Nguyen, Drew T. Bergman, Stephen Hinshaw, Nathan Cheng, Brian Cleary, Krishna Aragam, Eric S. Lander, Hilary K. Finucane, Debabrata Mukhopadhyay, Rajat M. Gupta and Jesse M. Engreitz, 7 February 2024, Nature.
DOI: 10.1038/s41586-024-07022-x

Authorship: Gavin R. Schnitzler (BWH; Broad Institute) and Helen Kang (Stanford Medicine) are co-first authors of this study. Gupta and Jesse M. Engreitz (Stanford Medicine; Broad Institute) are co-senior authors. Co-authors include Shi Fang, Ramcharan S. Angom, Vivian S. Lee-Kim, X. Rosa Ma, Ronghao Zhou, Tony Zeng, Katherine Guo, Martin S. Taylor, Shamsudheen K. Vellarikkal, Aurelie E. Barry, Oscar Sias-Garcia, Alex Bloemendal, Glen Munson, Philine Guckelberger, Tung H. Nguyen, Drew T. Bergman, Stephen Hinshaw, Nathan Cheng, Brian Cleary, Krishna Aragam, Eric S. Lander, Hilary K. Finucane, and Debabrata Mukhopadhyay.

Disclosures: Engreitz is a shareholder of Illumina and 10X Genomics, has received materials from 10X Genomics unrelated to this work, is an equity holder in and consultant for Martingale Labs, and has received guest speaker honoraria from GSK. Taylor holds equity and has received consulting fees from ROME Therapeutics, which is not related to this work. Schnitzler, Gupta, Engreitz, Kang, and Ma are inventors on a provisional patent related to this work.

Funding: This work was supported by the Variant-to-Function Initiative at the Broad Institute, the National Heart, Lung, and Blood Institute (R01HL159176, R01HL164811, U01HL166060), the National Human Genome Research Institute (UM1HG011972, R35HG011324), the Gordon and Betty Moore Foundation, the Basic Sciences and Engineering Initiative at the Lucile Packard Children’s Hospital at Stanford University, National Institutes of Health (K99HG009917, R00HG009917, DP2HL152423, HL70567, K08DK129824), the Novo Nordisk Foundation (NNF21SA0072102); the Harvard Society of Fellows; a Khoury Innovation Award and Braunwald Scholar Award; the Broad Institute, a Florida Department of Health Cancer Research Chair’s Fund Grant (3J-02 and (M.S.T).

2 Comments on "Hidden Genetic Triggers of Heart Disease Risk Unveiled"

  1. doctor mehrdad kesiri1389 | February 8, 2024 at 9:41 am | Reply


    ,The sun is located in the big arm of the galaxy. These two big arms of the galaxy are hundreds of times, at least, its systems that were formed from hundreds of millions of stars and small planets. The big arms of the galaxy will collide again with the sun and other solar bodies. You American scientists, especially NASA, were followers in astronomy. In the world, how did you not realize that hundreds of systems were swallowed by solar bodies and the sun, from the big arms of the planetary galaxy, they became 240 moons in the lap of the planets of the solar system, of course, a large number of these planets exploded when they collided with solar bodies and the sun itself, and After the disintegration of the elements of the small planets, the big arms of the galaxy turned into the belt of asteroids. All these traces of violent collisions with solar bodies are proof of this issue that we discovered, but Westerners should not ignore my discoveries.America must listen to God’s words, otherwise the people of America will not be able to stop a missile that hits an airplane, but they can go on the heads of those whose loved ones were killed by America and turn them against America like the people of Al-Qaeda. shoot down an airplane in the towers of America, in that suicide incident that was done by God, ten times more than two hundred and ninety people were killed. Americans shot down a passenger plane. God also killed 2,900 people in New York City in the west of America. Know that God’s stick has no sound, if it hits, there is no fight. God will work in time, but not in a moment

    The Americans should destroy the criminal Islamic Republic and end this dirty game. East and West, Khomeini’s forbidden bite was supported by Britain, France, and… England sent that parasite to Iran and brought misery and war to Iran. East and West for the poor and dead-worshipping nation of Iran, the people of Iran cannot overthrow the Akhund and take away the power from the Ayatollahs, Sheikhs and Mullahs, America must destroy the leader of Iran in a missile attack, the people have done nothing because the regime Haram Qamah and criminal mullahs are killing people by the mercenaries of the Sepahi and Basiji and other mercenary repressive agents of the Islamic Republic regimeThe Americans should not bother us so much. All the miseries of the believing and Muslim people are due to the extreme beliefs and bigotry of Shia Muslims of the Twelve Imams. The Lord of the Earth is asking me that the United States should strike the dictator and criminal of the Islamic Republic with a missile from the headquarters of the forbidden leader, and as soon as possible Remove the extreme corrupt leader from the people, we can’t bear it anymore, think about it, what would you do if such a calamity happened to you yourself, if America does not crush Khamenei, God and the Lord of the earth will take a severe revenge on America, like September 11 Time In iran is 9:11pm

    • kesiri1389sahebzaman | February 9, 2024 at 8:35 am | Reply

      The center of the body’s efforts is the heart.Most of the genetic heart diseases are prevalent, but half of the heart diseases are related to nutrition.Elderly people should not consume a lot of fat in their diet.My father had a vascular transplant at the age of 75, and my brother at the age of 57. At the age of 18, he performed a heart transplant operation.Now my father is 85 years old.My father and my brother’s profession was dentistry Time 8:05 pm

Leave a comment

Email address is optional. If provided, your email will not be published or shared.